Xin Lang Zheng Quan·2025-04-24 11:07Core Viewpoint - Shenwan Hongyuan has faced significant challenges in its IPO underwriting business, leading to a drastic decline in its performance and reputation due to regulatory issues and high project withdrawal rates [2][11][15]. Group 1: IPO Performance and Regulatory Issues - Shenwan Hongyuan's IPO underwriting income dropped by 97% in 2024 compared to 2023, with only one successful IPO project remaining [2][10]. - The company received seven penalties in 2024, a stark contrast to zero penalties in 2023, indicating a deterioration in compliance and operational standards [2][11]. - The IPO withdrawal rate reached 90% in 2024, significantly higher than the 33.3% rate in 2023, raising concerns about the firm's ability to maintain its A-class rating in the upcoming evaluations [11][15]. Group 2: Specific Cases of Regulatory Failures - Shenwan Hongyuan was criticized for its role in the IPO application of Guohong Tools, which was found to have falsified information regarding its R&D personnel and expenditures [3][4]. - The company failed to adequately verify the qualifications of R&D personnel, leading to a misrepresentation of the company's compliance with the Sci-Tech Innovation Board's requirements [4][5]. - Regulatory bodies have issued warnings and penalties against Shenwan Hongyuan for its inadequate due diligence and oversight in various projects, including the handling of the Hainuoer and Guohong Tools IPOs [16][17]. Group 3: Future Outlook - With only three IPO projects in total, including one from the Beijing Stock Exchange, Shenwan Hongyuan's competitive position in the IPO market is under scrutiny [9][10]. - The company's ability to recover its A-class rating in the 2025 evaluation is uncertain, given the current trajectory of its IPO performance and regulatory challenges [11][18].